Forward-thinking companies are able to work with Ora to make the most of this enormous opportunity to advance new ophthalmic anti-infective therapies into development.
Our core staff includes Ophthalmologists, PhDs, and experienced clinical trial managers
Our bulbar conjunctival redness scales were used in the approval of two recent NDAs for ocular anti-infectives
Unparalleled Infection Expertise
Our research team has extensive experience in efficacy, comfort, safety,
and pharmacokinetic studies
VP, Anti-infective, Glaucoma, AI, Retina
Ophthalmologists and optometrists always seek to provide their patients with the anti-infective therapy that provides the most potency against the causative ocular pathogens. Eye care providers take this level of precaution for fear of a serious infection that could threaten a patient’s vision, especially after eye surgery. For this reason, newer broad-spectrum anti-infectives with less resistance may offer an increased level of efficacy and patient safety.
Forward-thinking companies are able to work with Ora to make the most of this enormous opportunity to advance new ophthalmic anti-infective therapies into development. These clients include pharmaceutical companies with effective non-ophthalmic broad-spectrum compounds that can be re-purposed to suit an ophthalmic anti-infective profile. Companies look to Ora’s unique ability to both envision and seamlessly integrate pre-clinical, CMC, and clinical plans that can most efficiently maximize a compound’s therapeutic potential for the eye.